Clinical trial · Interventional
A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEGF0444A, Administered Intravenously to Patients With Advanced Solid Tumors
NCT00909740CI-TRIAL-00062631completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase I, first-in-human, open-label, dose-escalation study of MEGF0444A administered by IV infusion to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Cancers | Malignant Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MEGF0444A | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: MEGF0444A
Primary outcomes (2)
- measure
- Incidence and nature of dose-limiting toxicities (DLTs)
- timeFrame
- Days 1-21 of cycle 1
- measure
- Incidence, nature, relatedness, and severity of adverse events
- timeFrame
- Day 1 to study completion
Secondary outcomes (1)
- measure
- Pharmacokinetic parameters including total exposure, minimum and maximum serum concentration, clearance, and volume of distribution
- timeFrame
- Following administration of study drug
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically documented, incurable, or metastatic solid malignancy that has progressed on, or failed to respond to regimens or therapies known to provide clinical benefit Exclusion Criteria: * Inadequate hematologic and organ function * Anti-cancer therapy within 4 weeks prior to initiation of study treatment * Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except for alopecia * Active infection or autoimmune disease * Pregnancy (positive pregnancy test) or lactation
References
Publications (0)
Data not yet available
No reference posted for this study.